Phase 3 N=13 Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon
Type 1 Diabetes
Primary: Tmax — 23.8; 15.7 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial
Diabetic Macular Edema
Primary: Macular Thickness at 3 Days After Intravitreous Dexamethasone — 438.44; 465.22; 368.22 µm
Phase 3 N=49 A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
Diabetes Type 1
Primary: Rate of Infusion Set Failures — 0.05; 0.03 events per 30 participant days — p=0.375
N/A N=400 Brief Intervention for Rural Women at High Risk for HIV/HCV
Acquired Immune Deficiency Syndrome Virus · Hepatitis C · Drug Abuse
Primary: Number of Participants Having Unprotected Casual Sex — 27; 25 Participants
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
Phase 3 N=75 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
Diabetes Mellitus
Primary: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia — 100; 100 percentage of participants
N/A N=4 HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
HIV Infections
Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg
Phase 2 N=93 GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Previously Treated Metastatic Adenocarcinoma of the Pancreas
Primary: Overall Survival (OS) — 5.88; 6.11 months
N/A N=72 Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis
Psoriasis
Primary: Number of Participants With Serious Infections, Opportunistic Infections of Interest and Malignancies: Prospective Participants — 0; 0; 0 Participants
Phase 3 N=446 Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis (SAR)
Primary: Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score ( rTNSS) Over the 14-day Treatment Period — 8.83; 8.84; -2.2…
N/A N=15 Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment
Depression
Primary: Adherence to Antidepressant Medication — 0; 0; 0; 1 Participants
Phase 2 N=35 Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
Multiple Myeloma
Primary: Response Rates by Blade Criteria — 2; 5; 3; 2 Participants
Phase 2 N=10 The Role of TLR4 on Lipid-induced Insulin Resistance
Insulin Sensitivity
Primary: Effect of Eritoran on Muscle Insulin Sensitivity — 11.9; 10.2; 9.8 mg/kg/min — p=0.02
Phase 2 N=21 Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response
Phenylketonuria
Primary: Percent Change in Blood Phenylalanine — -13.71; -8.13; 48.75 Percent change in blood phenylalanine
Phase 3 N=9,901 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Cardiovascular Disease · Diabetes Mellitus, Type 2
Primary: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal…